This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dehm, S. M. Articles by Tindall, D. J. Search for Related Content PubMed PubMed Citation Articles by Dehm, S. M. Articles by Tindall, D. J.

Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer

Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Donald J. Tindall, Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905. E-mail: tindall.donald{at}mayo.edu.

The androgen receptor (AR) is a nuclear receptor transcription factor that mediates the cellular actions of androgens, the male sex steroids. Androgen-dependent tissues, such as the prostate, rely on androgen action for their development as well as their maintenance in adulthood. This requirement is exploited during systemic therapy of prostate cancer, which is initially an androgen-dependent disease. Indeed, androgen ablation, which prevents the production or blocks the action of androgens, inhibits prostate cancer growth. Invariably, the disease recurs with a phenotype resistant to further hormonal manipulations. However, this so-called androgen depletion-independent prostate cancer remains dependent on a functional AR for growth. Many studies have focused on the mechanistic and structural basis of AR activation with the important goal of understanding how the AR is activated at this stage of the disease. In this review, we summarize how these studies have revealed important functional domains in the AR protein and have provided initial clues to their role in prostate cancer development and progression. A comprehensive understanding of the role and functional relationships between these AR domains could lead to the development of novel AR-directed therapies for prostate cancer.

NURSA Molecule Pages Link:

Nuclear Receptors:   GR  |  AR

Coregulators:   UBC9  |  SRC-1  |  GRIP1  |  NCOR  |  SMRT

Ligands:   Dihydrotestosterone  |  Diethylstilbestrol  |  Bicalutamide

This article has been cited by other articles:

				F. Jin and J. D. Fondell A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression Nucleic Acids Res., June 11, 2009; (2009) gkp510v1. [Abstract] [Full Text] [PDF]

				M. Eisold, M. Asim, H. Eskelinen, T. Linke, and A. Baniahmad Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens J. Mol. Endocrinol., May 1, 2009; 42(5): 429 - 435. [Abstract] [Full Text] [PDF]

				D. J. Vander Griend, L. Antony, S. L. Dalrymple, Y. Xu, S. B. Christensen, S. R. Denmeade, and J. T. Isaacs Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells Mol. Cancer Ther., May 1, 2009; 8(5): 1340 - 1349. [Abstract] [Full Text] [PDF]

				J.-C. Pignon, B. Koopmansch, G. Nolens, L. Delacroix, D. Waltregny, and R. Winkler Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines Cancer Res., April 1, 2009; 69(7): 2941 - 2949. [Abstract] [Full Text] [PDF]

				J Yang, Y-L Zhao, Z-Q Wu, Y-L Si, Y-G Meng, X-B Fu, Y-M Mu, and W-D Han The single-macro domain protein LRP16 is an essential cofactor of androgen receptor Endocr. Relat. Cancer, March 1, 2009; 16(1): 139 - 153. [Abstract] [Full Text] [PDF]

				R. Hu, T. A. Dunn, S. Wei, S. Isharwal, R. W. Veltri, E. Humphreys, M. Han, A. W. Partin, R. L. Vessella, W. B. Isaacs, et al. Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer Cancer Res., January 1, 2009; 69(1): 16 - 22. [Abstract] [Full Text] [PDF]

				H. Zhang, M. H. Muders, J. Li, F. Rinaldo, D. J. Tindall, and K. Datta Loss of NKX3.1 Favors Vascular Endothelial Growth Factor-C Expression in Prostate Cancer Cancer Res., November 1, 2008; 68(21): 8770 - 8778. [Abstract] [Full Text] [PDF]

				N. Khan, M. Asim, F. Afaq, M. Abu Zaid, and H. Mukhtar A Novel Dietary Flavonoid Fisetin Inhibits Androgen Receptor Signaling and Tumor Growth in Athymic Nude Mice Cancer Res., October 15, 2008; 68(20): 8555 - 8563. [Abstract] [Full Text] [PDF]

				S. M. Wiseman, A. Melck, H. Masoudi, F. Ghaidi, L. Goldstein, A. Gown, S. J. M. Jones, and O. L. Griffith Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis Ann. Surg. Oncol., October 1, 2008; 15(10): 2811 - 2826. [Abstract] [Full Text] [PDF]

				S. M. Dehm, L. J. Schmidt, H. V. Heemers, R. L. Vessella, and D. J. Tindall Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance Cancer Res., July 1, 2008; 68(13): 5469 - 5477. [Abstract] [Full Text] [PDF]